Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome by Andrea Sarkozy, Tim Boussy, Georgios.

Published byAlexandrina Dean Modified over 8 years ago

Similar presentations

Presentation on theme: "Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome by Andrea Sarkozy, Tim Boussy, Georgios."— Presentation transcript:

1 Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome by Andrea Sarkozy, Tim Boussy, Georgios Kourgiannides, Gian-Battista Chierchia, Sergio Richter, Tom De Potter, Peter Geelen, Francis Wellens, Marieke Dingena Spreeuwenberg, and Pedro Brugada EHJ Volume 28(3):334-344 February 5, 2007 © The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

2 Examples of positive ajmaline test results. Andrea Sarkozy et al. Eur Heart J 2007;28:334-344 © The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

3 (A) Kaplan–Meier appropriate shock-free survival analysis in the study population. Andrea Sarkozy et al. Eur Heart J 2007;28:334-344 © The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

4 Example of initiation of monomorphic VT in a 64-year-old male patient taking quinidine therapy. Andrea Sarkozy et al. Eur Heart J 2007;28:334-344 © The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

5 (A) Kaplan–Meier IS-free survival analysis in the study population. Andrea Sarkozy et al. Eur Heart J 2007;28:334-344 © The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

6 Examples of IS for atrial arrhythmias with fast ventricular rates. Andrea Sarkozy et al. Eur Heart J 2007;28:334-344 © The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Download ppt "Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome by Andrea Sarkozy, Tim Boussy, Georgios."

Similar presentations

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the.

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the.
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies by Lawrence de Koning,

Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies by Lawrence de Koning,
B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode by Guillaume.

B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode by Guillaume.
The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH by Antigone.

The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH by Antigone.
B-type natriuretic peptide in paediatric patients with congenital heart disease by Andreas Koch, Stefan Zink, and Helmut Singer EHJ Volume 27(7):861-866.

B-type natriuretic peptide in paediatric patients with congenital heart disease by Andreas Koch, Stefan Zink, and Helmut Singer EHJ Volume 27(7):
An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study by Peter Barlis, Evelyn.

An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study by Peter Barlis, Evelyn.
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial by Atul Verma, Roberto Mantovan,

Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial by Atul Verma, Roberto Mantovan,
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography by Daisuke Matsumoto, Junya Shite, Toshiro.

Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography by Daisuke Matsumoto, Junya Shite, Toshiro.
Remote monitoring and follow-up of pacemakers and implantable cardioverter defibrillators by Haran Burri, and David Senouf Europace Volume 11(6):701-709.

Remote monitoring and follow-up of pacemakers and implantable cardioverter defibrillators by Haran Burri, and David Senouf Europace Volume 11(6):
Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter by Lluís Mont, Roberto Elosua, and Josep Brugada Europace Volume 11(1):11-17.

Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter by Lluís Mont, Roberto Elosua, and Josep Brugada Europace Volume 11(1):11-17.
Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a.

Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a.
High spatial resolution myocardial perfusion cardiac magnetic resonance for the detection of coronary artery disease by Sven Plein, Sebastian Kozerke,

High spatial resolution myocardial perfusion cardiac magnetic resonance for the detection of coronary artery disease by Sven Plein, Sebastian Kozerke,
Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia by András Vereckei, Gábor Duray, Gábor Szénási, Gregory T.

Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia by András Vereckei, Gábor Duray, Gábor Szénási, Gregory T.
Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting by Corrado Tamburino, Gian Paolo Ussia, Francesco Maisano,

Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting by Corrado Tamburino, Gian Paolo Ussia, Francesco Maisano,
Coronary computed tomography angiography with a consistent dose below 1 mSv using prospectively electrocardiogram-triggered high-pitch spiral acquisition.

Coronary computed tomography angiography with a consistent dose below 1 mSv using prospectively electrocardiogram-triggered high-pitch spiral acquisition.
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer.

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer.
Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment.

Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment.
Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy by Christian Templin,

Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy by Christian Templin,
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with.

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with.
Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January.

Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January.

Similar presentations

Ads by Google